Mansinh Chaudhari purchased Medicare beneficiary information and sold it to healthcare providers who then submitted unnecessary COVID-19 tests for those beneficiaries.

The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.

News items for the week of Dec. 9, 2024.

The new Cobas 6800/8800 systems 2.0 enhances throughput and run flexibility and enables sample prioritization.

The Dutch firm will develop assays for syphilis and tuberculosis using its infrared light-based protein detection technology.

The company will distribute products from Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics, and Asuragen brands.

The German firm said that it plans to launch its AltoStar Parvovirus B19 PCR Kit 1.5 in January and other unspecified tests through spring of 2025.

Analysts noted that while continued double-digit growth appears unsustainable in the near term, risks related to UnitedHealthcare's decision on pharmacogenetic testing appear limited.

The deal involves the implementation in Limbach Group labs of Noul's automated MiLab instrument that uses microscopy and AI-developed algorithms to analyze samples.

The organization now recommends HPV primary screening every five years starting at age 30 and includes patient-collected HPV screening.